Tests HQP1351 pill in adults with resistant chronic myeloid or Ph+ leukemia
Tests the oral drug HQP1351 in adults with leukemia that stopped responding to earlier treatments.
Key facts
- Who runs it
- Ascentage Pharma Group Inc.
- Where
- Atlanta, Augusta, Baltimore, Birmingham, Cleveland, Duarte, Houston, and Seattle, United StatesSee the 8 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 242 people, planned
- Started
- 9 Jan 2020
- Expected to end
- 31 Mar 2030
- Type of study
- Interventional, 4 groups
- Treatments tested
- Ascentage Pharma HQP1351 bioavailable inhibitor
- Blinatumomab
- Record updated
- 5 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (Ph+ ALL) whose disease no longer responds to, or who cannot tolerate, earlier targeted drugs called TKIs.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- CML in any phase (chronic, accelerated or blast phase) or Ph+ ALL, with or without the T315I mutation. Cohort D: Ph+ B-cell precursor ALL or lymphoid blast phase CML.
- Earlier treatment
- Must have had at least two TKIs (such as imatinib, dasatinib, nilotinib, bosutinib, ponatinib or asciminib) without success or with side effects. With a T315I mutation, the number of earlier TKIs is not restricted. Cohort D: at least one second or later generation TKI.
- Biomarker or test result
- Ph+ disease (Philadelphia chromosome). The T315I mutation may be present or absent.
Main reasons for not taking part
- Stem cell transplant in the past, active graft-versus-host disease, or recent immune suppression
- Serious or active heart disease, such as a heart attack in the last 6 months or heart failure
- Active infection, including HIV, hepatitis B or hepatitis C
- Leukemia cells confirmed in the central nervous system
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- For HQP1351 monotherapy, patients must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL, with or without T315I mutation
- For Cohort D, patients with Ph+ BCP ALL or CML LBP must be resistant or intolerant to at least one second or later generation TKI, such as dasatinib, nilotinib, bosutinib and ponatinib, despite optimal supportive care
- For HQP1351 monotherapy only: Be previously treated with and developed resistance or intolerance to at least two TKIs including ponatinib, imatinib, dasatinib, nilotinib, bosutinib, and asciminib. For patients with a T315I mutation, number of pretreated TKIs is not restricted; The definition of resistance to first-line TKI treatment refers to European Leukemia Net (ELN) recommendations. The definitions are the same for patients in CP, AP, BP, and Ph+ ALL, and apply also to second-line treatment, when first-line treatment was changed for intolerance. The patients must meet at least one criterion:; Three months after the initiation of therapy: non-complete hematologic response (CHR) and/or Ph+ >95%; Six months after the initiation of therapy: BCR-ABL1>10% and/or Ph+ >35%; Twelve months after the initiation of therapy: BCR-ABL1>1% and/or Ph+ >0%; Then, and at any time after the initiation of therapy: Loss of CHR, or loss of complete cytogenetic response (CCyR), or confirmed loss of major molecular response (MMR) (In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level ≥1%), mutations, clonal chromosome abnormalities in Ph+ cells (CCA/Ph+); The definition of resistance to second-line TKI treatment; For CML CP patients: the patients must meet at least one criterion as follows:; i.) Three months after the initiation of therapy: No CHR or Ph+ >95% or new mutations; ii.) Six months after the initiation of therapy: BCR-ABL1>10% and/or Ph+ >65% and/or new mutations; iii.) Twelve months after the initiation of therapy: BCR-ABL1>1% and/or Ph+ >35% and/or new mutations; iv.) Then, and at any time after the initiation of therapy: Loss of CHR or loss of CCyR, new mutations, confirmed loss of MMR (In 2 consecutive tests, of which one with a BCR-ABL1 transcripts level ≥1%), clonal chromosome abnormalities in Ph+ cells (CCA/Ph+); For CML AP patients: the patients must meet at least one criterion as follows:; i.) Three months after the initiation of therapy: failure to achieve a major hematologic response (MaHR); ii.) At any time after the initiation of therapy, the loss of a MaHR, confirmed in at least 2 consecutive analyses separated by at least 4 weeks; iii.) At any time after the initiation of therapy, the development of new BCR-ABL kinase domain mutations in the absence of a MaHR; For CML BP and Ph+ ALL patients: the patients must meet at least one criterion as follows:; One month after the initiation of therapy: failure to achieve a MaHR; At any time after the initiation of therapy, the loss of a MaHR, confirmed in at least 2 consecutive analyses separated by at least 1 week; At any time after the initiation of therapy, the development of new BCR-ABL kinase domain mutations in the absence of a MaHR; Intolerance to TKIs is defined as:; Non-hematological AEs: patients with grade 3 or 4 toxicity during TKIs treatment, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments in the absence of a CCyR for CP patients or MaHR for AP/BP or Ph+ ALL patients; Hematological AEs: patients with grade 3 or 4 toxicity during TKIs treatment, that is recurrent after unresponsive after optimal management, including dose adjustments in the absence of a CCyR for CP patients or MaHR for AP/BP or Ph+ ALL patients
- Patients providing written informed consent before initiation of any study-related activities
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Minimum life expectancy of 3 months or more
- Patients with adequate organ function as defined below:; Creatinine < 2 × upper limit of normal (ULN); or, creatinine > 2 × ULN, with 24h glomerular filtration rate (GFR) ≥ 30 mL/min (Cockcroft-Gault); Serum albumin ≥ 3.0 g/dL; Total bilirubin < 1.5 × ULN; Aspartate aminotransferase (AST [Serum glutamic oxaloacetic transaminase (SGOT)]) and alanine aminotransferase (ALT [serum glutamate-pyruvate transaminase (SGPT)]) < 3 × ULN for institution (<5×ULN if liver involvement with leukemia); Serum amylase and lipase ≤ 1.5 × ULN; Prothrombin time (PT) ≤ 1.5 × ULN
- Heart function: Left ventricular ejection fraction (LVEF) > 50%
- Normal QT interval corrected Fridericia (QTcF) interval on screening electrocardiogram (ECG) evaluation: male ≤450ms, female ≤470ms
- For females of childbearing potential, a negative pregnancy test must be established before enrollment. And the eligible female and male patients with childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study
- Ability to comply with study procedures, in the Investigator's opinion
Who cannot take part
- Received TKI therapy within 5 half-lives or 7 days prior to first dose of HQP1351, whichever is shorter, or any adverse events (AEs) (except alopecia and pigmentation) not recovered to CTCAE v5.0 grade 0-1 due to any other treatments
- Received other therapies as follows:; For CP and AP patients, received hydroxyurea or anagrelide within 24 hours prior to the first dose of HQP1351; or, interferon, immunotherapy or cytarabine within 14 days prior to the first dose of HQP1351; or, any other radiotherapy, cytotoxic chemotherapy or investigational therapy within 28 days prior to receiving the first dose of HQP1351; For BP patients, received chemotherapy within 7 days prior to the first dose of HQP1351; For Ph+ ALL patients, received corticosteroids within 24 hours before the first dose of HQP1351, or received chemotherapy within 7 days prior to the first dose of HQP1351; Patients who are currently receiving treatment with a medication that has the potential to interact with HQP1351; Patients who had been treated with HQP1351; Patients requiring immunosuppressive therapy other than short time of steroid
- Have history of autologous or allogeneic stem cell transplant, or with active graft-versus-host disease (GVHD), or active immune suppression in recent 6 months prior to informed consent date or active immune suppression in recent 6 months prior to informed consent date
- Patients who had a major surgery within 4 weeks prior to study entry or have not recovered from side effects of such surgery which the Investigator considers not appropriate for enrollment
- Cytologically confirmed central nervous system (CNS) involvement (if asymptomatic, spinal fluid examination is not necessary prior to first treatment)
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs
- Patients who have a significant bleeding disorder unrelated to CML or Ph+ ALL
- Patients with another primary malignancy within 1 year of study entry. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry
- Have ongoing or active infection, including known history of immunodeficiency virus (HIV) or HIV antibody positive, hepatitis B virus (HBV) or HBsAg positive, hepatitis C virus (HCV). Patients who have positive HCV antibody must have an undetectable HCV viral load
- Patients with COVID-19 who now present with positive swab
- Known allergy to any components in the study drug
- Patients who have any conditions or illness that, according to the opinions of the investigator or the medical monitor, would comprise patient safety or interfere with the evaluation of safety and efficacy to the study drug
- Patients with cardiovascular diseases, including uncontrolled high blood pressure (HBP) (that is blood pressure >140/90mmHg.); or, receiving drugs that can cause prolonged QT interval. Patients with well controlled HBP can be considered to be included. ("well controlled HBP" is defined as: HBP can be ≤ 140/90mmHg with antihypertensive treatment). Those requiring 3 or more antihypertensive medications should be discussed with the medical monitor
- Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:; Any history of myocardial infarction (MI) within 6 months or unstable angina within 3 months; Any history of cerebrovascular accident within 1 year, or transient ischemic attack (TIA) within 3 months; Any history of peripheral vascular infarction, including visceral infarction within 6 months; Congestive heart failure (CHF) (New York Heart Association [NYHA] class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment; History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia; Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 3 months prior to enrollment. Patients who have experienced a venous thromboembolic event should only be eligible if the condition is well controlled with optimal intervention (as determined by the treating physician). Continued prophylactic anticoagulation is acceptable; Patients with revascularization procedures including cardiac bypass within the 6 months and stenting within the past 3 months should be excluded
- Patients who have poorly controlled diabetes, defined as HbA1C values of > 7.5%. Patients with pre-existing, well-controlled diabetes are not excluded
- CML CP patients with CCyR
- Pregnant or lactating
Where in United States
Also in 1 other country, 1 site
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesContact: Shannon GleasonTaking people
- Augusta Cancer CenterAugusta, United StatesContact: Amanda SpiresTaking people
- University of MarylandBaltimore, United StatesContact: Amelia BarkmanTaking people
- University of Alabama at BirminghamBirmingham, United StatesContact: Sarah WeaverTaking people
- Cleveland ClinicCleveland, United StatesContact: Erik LewerenzTaking people
- City of HopeDuarte, United StatesContact: Paul Koller, MD (principal investigator)Taking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Jovitta JacobTaking people
- Fred Hutchinson Cancer Research CenterSeattle, United StatesContact: Kaysey OrlowskiTaking people
About the trial
What the trial wants to find out
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolerance to at least one second or later generation TKI.
The 4 groups in the trial
- Cohort ATreatment being tested
Treatment: Ascentage Pharma HQP1351 bioavailable inhibitor
- Cohort BTreatment being tested
Treatment: Ascentage Pharma HQP1351 bioavailable inhibitor
- Cohort CTreatment being tested
Treatment: Ascentage Pharma HQP1351 bioavailable inhibitor
- Cohort DTreatment being tested
Treatment: Ascentage Pharma HQP1351 bioavailable inhibitor and Blinatumomab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)
- Plain-language title
- Tests HQP1351 pill in adults with resistant chronic myeloid or Ph+ leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.JAMA oncology, 2025
- Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.Journal of hematology & oncology, 2022
- Record updated
- 5 November 2025